The battle between cancer and the immune system: who switches the off signals off?
Posted on 2 November 2017
Their research revealed a trick that healthy cells use to prevent undue suppression of the immune response.
The study, by scientists from the University of York, the Hull York Medical School and Barts Cancer Institute, Queen Mary University of London, could lead to improved use and management of cancer immunotherapies.
Our immune system has a remarkable potential to clear pre-cancerous or cancer cells. However, often cancer cells develop the ability to emit ‘off’ signals to immune cells and fool them into apathy.
Immune checkpoints
These ‘off’ signals are called ‘immune checkpoints’. In the last five years, the way we treat cancer has been transformed by developing drugs that try to stop these off signals and reawaken our immune system.
The research centred on PDL1, an ‘immune checkpoint’ protein and prominent target of cancer immunotherapies.
The researchers were inspired by the fact that immune checkpoints are not just present in cancer cells. They exist naturally in our body to prevent immune cells from prolonged or unnecessary immune responses, for example autoimmunity (where our immune system attacks our own cells).
Based on this observation, rather than exploring how immune checkpoints are controlled in cancer cells, the researchers went back and asked how the immune checkpoint protein PDL1 is controlled in normal non-cancerous cells.
By understanding the normal biology of this important drug target, the investigators hoped to gain new insight into ways of “rewiring” cancer cells in a manner that would render them susceptible to immune attack.
Immunologist Dr Dimitris Lagos of the Centre for Immunology and Infection, which is part of the University of York’s Department of Biology and Hull York Medical School, led the research.
Dr Lagos said: “We wanted to find mechanisms that suppress the levels of PDL1 in healthy cells. Remarkably, we discovered that miR-155, a tiny biomolecule from a family of genes called microRNAs, keeps a check on PDL1 levels.
“Interestingly, miR-155 has been known to be a key regulator of immunity for almost a decade. However, its connection to the immune checkpoint function has eluded scientists. This discovery has the potential to help us come up with more effective anti-cancer immunotherapies”
New discovery
Dr Tyson V. Sharp of Barts Cancer Institute, Queen Mary University of London, who collaborated with Dr Lagos in the study said: “Immuno-oncology, the study of anti-cancer immunity, is a highly active research space in cancer medicine.
“This exciting finding opens up new avenues of investigation that we believe can help us develop novel and more effective treatments for cancer, including cancers of unmet needs, such as lung and pancreatic cancer. More work is needed to reveal the full potential of this new discovery.”
The study is published in the Journal of Biological Chemistry.
Explore more news
York to lead effort to provide solar energy in Africa
Wednesday 18 December 2024
University of York to lead research to transform adult social care following new £31m investment
Wednesday 18 December 2024
York joins North Sea University Partnership
Tuesday 17 December 2024
Pioneering virtual field trips are supporting higher education in Ukraine
Tuesday 17 December 2024
Study finds the UK’s inland bathing sites are polluted with a ‘perfect storm’ of chemicals and antibiotic resistant genes
Monday 16 December 2024
Media enquiries
About this research
A team of immunologists with the Centre for Immunology and Infection, part of the University of York’s Department of Biology and Hull York Medical School, has presented new research on cancer immune checkpoints.
The team included Dr Dimitris Lagos a Senior Lecturer in Immunology, PhD student Daniel Yee, and Professor Mark Coles.
Presented in the Journal of Biological Chemistry, the research was carried out in collaboration with the Barts Cancer Institute, Queen Mary University of London.
The research was funded by the Medical Research Council (MR/L008505/1) and the Biotechnology and Biological Sciences Research Council (B/J01113/1 and BB/I007571/2).